December 5-7th, 2017

Miami, FL


The 3rd Annual Oncolytic Virotherapy Summit is the leading end-to-end industry focused gathering dedicated to bringing through clinic the next generation of immuno-oncolytic virotherapies for use in combinations.

The Oncolytic Virotherapy Summit sets the stage for oncolytic viruses to step into the limelight as the much-needed TME and immune modulating combination therapeutic of choice. NEW for 2017:

  • Gather the leaders in immuno-oncolytic virus development discussing the most up to date clinical advances at late stage phase 3 alongside the novel innovation being made in genetically modifying the viruses with multiple transgenes.
  • Map out the route to market focusing on the strategic advancements needed to improve viral manufacturing yield and scale along with the operational and logistical aspects of delivering an oncolytic virotherapy to patients in need.
  • Present the most cutting edge advancements in novel combination trials from check point modulators through to CAR-T therapies.

Attend this only industry-focused gathering to enhance the translation of innovative basic research into the next generation of clinically-relevant virotherapeutics. Register your interest to gain exclusive access to the early registration rates and confidential real-time updates on the agenda.


"This summit provided great talks. Topics were focused and inspiring. The oncolytic virotherapy community was enthusiastic and full of ideas." -
MIT | 2016 Attendee

“Extremely useful conference to meet other players in the modern OV development, which will make a change in how we are going to treat diseases like cancer.” - Boehringer Ingelheim | 2016 Attendee

Linkedin Oncolytic Virotherapy Summit

Media Partner